Efficacy of a novel experimental antibody in a humanized mouse model of psoriasis
Recruiting
- Conditions
- flaking diseasepsoriasis1000381610014982
- Registration Number
- NL-OMON34037
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
Psoriasis patients: Adults (m/f) with a mild form of psoriasis vulgaris (PASI score of maximal 6). Patients are allowed to use local corticosteroids or ointments to prevent dry skin (see Appendix 2).
Exclusion Criteria
Psoriasis patients: These patients have not received light therapy or another form of systemic treatment (methotrexate, cyclosporin A, anti-TNF treatments). Gender or age of the adults are not considered as exclusion criteria (see Appendix 2).
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The effect of treatment on the psoriatic process is tested by histological and<br /><br>immuno-histochemical techniques in the transplanted biopsies. The main read-out<br /><br>is epidermal thickness.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Serum markers in blood of transplanted mice will be studied together with<br /><br>markers on cultured cells from psoriasis patients.<br /><br>Markers of inflammation in serum or RNA isolated from blood cells and in the<br /><br>skin.</p><br>